Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1994 Jul;145(1):97–104.

Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression.

J A Reed 1, N S McNutt 1, V G Prieto 1, A P Albino 1
PMCID: PMC1887285  PMID: 8030760

Abstract

Transforming growth factor-beta 2 (TGF-beta 2) is a potent regulatory of proliferation and differentiation of both normal and malignant cells. In addition, TGF-beta 2 can exert a variety of immunosuppressive effects, suggesting that the production of this molecule contributes to impaired immunological surveillance of tumor development. In vitro, TGF-beta 2 expression has been demonstrated in cell lines derived from metastatic malignant melanocytes. but not in those derived from normal melanocytes. We sought to evaluate a potential role of TGF-beta 2 in the initiation or progression of malignant melanoma in vivo. We examined by nucleic acid in situ hybridization the expression of TGF-beta 2 mRNA transcripts in 124 melanocytic lesions including metastatic and primary invasive melanomas, melanomas in situ, nevi with architectural disorder and cytologic atypia, ordinary benign melanocytic nevi, and Spitz nevi. All metastatic melanomas and a majority (94%) of primary melanomas invasive to Clark's level III, IV, or V expressed TGF-beta 2 mRNA. A minority (41%) of Clark's level II primary invasive melanomas expressed this factor. All definitive melanomas in situ and nevi were negative. The results suggest that TGF-beta 2 expression in malignant melanoma may be a critical event in the development of deep invasion and metastases in malignant melanoma.

Full text

PDF
97

Images in this article

100Figure 1
on p.100
102Figure 3
on p.102

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaronson S. A. Growth factors and cancer. Science. 1991 Nov 22;254(5035):1146–1153. doi: 10.1126/science.1659742. [DOI] [PubMed] [Google Scholar]
  2. Albelda S. M., Mette S. A., Elder D. E., Stewart R., Damjanovich L., Herlyn M., Buck C. A. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res. 1990 Oct 15;50(20):6757–6764. [PubMed] [Google Scholar]
  3. Albino A. P., Davis B. M., Nanus D. M. Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. Cancer Res. 1991 Sep 15;51(18):4815–4820. [PubMed] [Google Scholar]
  4. Arrick B. A., Korc M., Derynck R. Differential regulation of expression of three transforming growth factor beta species in human breast cancer cell lines by estradiol. Cancer Res. 1990 Jan 15;50(2):299–303. [PubMed] [Google Scholar]
  5. Bodmer S., Strommer K., Frei K., Siepl C., de Tribolet N., Heid I., Fontana A. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol. 1989 Nov 15;143(10):3222–3229. [PubMed] [Google Scholar]
  6. Bucana C. D., Radinsky R., Dong Z., Sanchez R., Brigati D. J., Fidler I. J. A rapid colorimetric in situ mRNA hybridization technique using hyperbiotinylated oligonucleotide probes for analysis of mdr1 in mouse colon carcinoma cells. J Histochem Cytochem. 1993 Apr;41(4):499–506. doi: 10.1177/41.4.8095509. [DOI] [PubMed] [Google Scholar]
  7. Clark W. H., Jr, Elder D. E., Guerry D., 4th, Braitman L. E., Trock B. J., Schultz D., Synnestvedt M., Halpern A. C. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989 Dec 20;81(24):1893–1904. doi: 10.1093/jnci/81.24.1893. [DOI] [PubMed] [Google Scholar]
  8. Coffey R. J., Jr, Goustin A. S., Soderquist A. M., Shipley G. D., Wolfshohl J., Carpenter G., Moses H. L. Transforming growth factor alpha and beta expression in human colon cancer lines: implications for an autocrine model. Cancer Res. 1987 Sep 1;47(17):4590–4594. [PubMed] [Google Scholar]
  9. Czarniecki C. W., Chiu H. H., Wong G. H., McCabe S. M., Palladino M. A. Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol. 1988 Jun 15;140(12):4217–4223. [PubMed] [Google Scholar]
  10. Ellingsworth L. R., Nakayama D., Segarini P., Dasch J., Carrillo P., Waegell W. Transforming growth factor-beta s are equipotent growth inhibitors of interleukin-1-induced thymocyte proliferation. Cell Immunol. 1988 Jun;114(1):41–54. doi: 10.1016/0008-8749(88)90253-5. [DOI] [PubMed] [Google Scholar]
  11. Folkman J., Klagsbrun M. Angiogenic factors. Science. 1987 Jan 23;235(4787):442–447. doi: 10.1126/science.2432664. [DOI] [PubMed] [Google Scholar]
  12. Gatherer D., Ten Dijke P., Baird D. T., Akhurst R. J. Expression of TGF-beta isoforms during first trimester human embryogenesis. Development. 1990 Oct;110(2):445–460. doi: 10.1242/dev.110.2.445. [DOI] [PubMed] [Google Scholar]
  13. Gromet M. A., Epstein W. L., Blois M. S. The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer. 1978 Nov;42(5):2282–2292. doi: 10.1002/1097-0142(197811)42:5<2282::aid-cncr2820420528>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  14. Huber D., Philipp J., Fontana A. Protease inhibitors interfere with the transforming growth factor-beta-dependent but not the transforming growth factor-beta-independent pathway of tumor cell-mediated immunosuppression. J Immunol. 1992 Jan 1;148(1):277–284. [PubMed] [Google Scholar]
  15. Iezzoni J. C., Kang J. H., Montone K. T., Reed J. A., Brigati D. J. Colorimetric detection of herpes simplex virus by DNA in situ sandwich hybridization: a rapid, formamide-free, random oligomer-enhanced method. Nucleic Acids Res. 1992 Mar 11;20(5):1149–1150. doi: 10.1093/nar/20.5.1149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ikeda T., Lioubin M. N., Marquardt H. Human transforming growth factor type beta 2: production by a prostatic adenocarcinoma cell line, purification, and initial characterization. Biochemistry. 1987 May 5;26(9):2406–2410. doi: 10.1021/bi00383a002. [DOI] [PubMed] [Google Scholar]
  17. Johnson J. P., Stade B. G., Holzmann B., Schwäble W., Riethmüller G. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci U S A. 1989 Jan;86(2):641–644. doi: 10.1073/pnas.86.2.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lehmann J. M., Riethmüller G., Johnson J. P. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A. 1989 Dec;86(24):9891–9895. doi: 10.1073/pnas.86.24.9891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Levine J. H., Moses H. L., Gold L. I., Nanney L. B. Spatial and temporal patterns of immunoreactive transforming growth factor beta 1, beta 2, and beta 3 during excisional wound repair. Am J Pathol. 1993 Aug;143(2):368–380. [PMC free article] [PubMed] [Google Scholar]
  20. Lyons R. M., Gentry L. E., Purchio A. F., Moses H. L. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol. 1990 Apr;110(4):1361–1367. doi: 10.1083/jcb.110.4.1361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Madisen L., Webb N. R., Rose T. M., Marquardt H., Ikeda T., Twardzik D., Seyedin S., Purchio A. F. Transforming growth factor-beta 2: cDNA cloning and sequence analysis. DNA. 1988 Jan-Feb;7(1):1–8. doi: 10.1089/dna.1988.7.1. [DOI] [PubMed] [Google Scholar]
  22. Massagué J. The TGF-beta family of growth and differentiation factors. Cell. 1987 May 22;49(4):437–438. doi: 10.1016/0092-8674(87)90443-0. [DOI] [PubMed] [Google Scholar]
  23. Miyazono K., Hellman U., Wernstedt C., Heldin C. H. Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem. 1988 May 5;263(13):6407–6415. [PubMed] [Google Scholar]
  24. Moses H. L., Yang E. Y., Pietenpol J. A. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell. 1990 Oct 19;63(2):245–247. doi: 10.1016/0092-8674(90)90155-8. [DOI] [PubMed] [Google Scholar]
  25. NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA. 1992 Sep 9;268(10):1314–1319. doi: 10.1001/jama.1992.03490100112037. [DOI] [PubMed] [Google Scholar]
  26. Natali P. G., Nicotra M. R., Bartolazzi A., Mottolese M., Coscia N., Bigotti A., Zardi L. Expression and production of tenascin in benign and malignant lesions of melanocyte lineage. Int J Cancer. 1990 Oct 15;46(4):586–590. doi: 10.1002/ijc.2910460406. [DOI] [PubMed] [Google Scholar]
  27. Paladugu R. R., Yonemoto R. H. Biologic behavior of thin malignant melanomas with regressive changes. Arch Surg. 1983 Jan;118(1):41–44. doi: 10.1001/archsurg.1983.01390010031008. [DOI] [PubMed] [Google Scholar]
  28. Radinsky R., Bucana C. D., Ellis L. M., Sanchez R., Cleary K. R., Brigati D. J., Fidler I. J. A rapid colorimetric in situ messenger RNA hybridization technique for analysis of epidermal growth factor receptor in paraffin-embedded surgical specimens of human colon carcinomas. Cancer Res. 1993 Mar 1;53(5):937–943. [PubMed] [Google Scholar]
  29. Reed J. A., Manahan L. J., Park C. S., Brigati D. J. Complete one-hour immunocytochemistry based on capillary action. Biotechniques. 1992 Sep;13(3):434–443. [PubMed] [Google Scholar]
  30. Roberts A. B., Sporn M. B., Assoian R. K., Smith J. M., Roche N. S., Wakefield L. M., Heine U. I., Liotta L. A., Falanga V., Kehrl J. H. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4167–4171. doi: 10.1073/pnas.83.12.4167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Ronan S. G., Eng A. M., Briele H. A., Shioura N. N., Das Gupta T. K. Thin malignant melanomas with regression and metastases. Arch Dermatol. 1987 Oct;123(10):1326–1330. [PubMed] [Google Scholar]
  32. Tada T., Ohzeki S., Utsumi K., Takiuchi H., Muramatsu M., Li X. F., Shimizu J., Fujiwara H., Hamaoka T. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol. 1991 Feb 1;146(3):1077–1082. [PubMed] [Google Scholar]
  33. Torre-Amione G., Beauchamp R. D., Koeppen H., Park B. H., Schreiber H., Moses H. L., Rowley D. A. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A. 1990 Feb;87(4):1486–1490. doi: 10.1073/pnas.87.4.1486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Woods J. E., Soule E. H., Creagan E. T. Metastasis and death in patients with thin melanomas (less than 0.76 mm). Ann Surg. 1983 Jul;198(1):63–64. doi: 10.1097/00000658-198307000-00012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wrann M., Bodmer S., de Martin R., Siepl C., Hofer-Warbinek R., Frei K., Hofer E., Fontana A. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J. 1987 Jun;6(6):1633–1636. doi: 10.1002/j.1460-2075.1987.tb02411.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. de Vries T. J., Quax P. H., Denijn M., Verrijp K. N., Verheijen J. H., Verspaget H. W., Weidle U. H., Ruiter D. J., van Muijen G. N. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol. 1994 Jan;144(1):70–81. [PMC free article] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES